The Vector Expedited Review Voucher (VERV), modelled on the already established US Priority Review Voucher (PRV) for drug development, is a proposed no cost new incentive to encourage R&D focussed agriculture companies to innovate in public health where there are significant economic barriers to product innovation. The VERV would encourage companies to invest in novel insecticide development for public health, such as malaria, by rewarding the registrant of a new public health insecticide with a voucher to receive an expedited review of a second, more profitable product outside public health. Getting to market faster is valuable and gives an innovator registrant an opportunity to generate a financial return to mitigate the development cost losses on a public health use insecticide.IVCC supports Malaria No More UK report: How British-backed science can accelerate the end of malaria 29th October 2021
The report features a Foreword by Sir Stephen O’Brien, Chair of the IVCC Board of Trustees and two cases studies of product innovation in vector control; Westham’s Attractive Targeted Sugar bait (ATSB®) and BASF’s Interceptor® G2 dual insecticide bed net. IVCC is a Product Development Partnership (PDP) based in Liverpool which works with the private sector, academics and funders to advance the development and deployment of a range of innovative vector control tools to help eradicate malaria. Read the full report here.
IVCC welcomes RTS,S malaria vaccine announcement 12th October 2021
IVCC enthusiastically welcomes the news that the World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and other regions.
IVCC would like to congratulate the many organisations that have worked together to reach this historical milestone. It is another example of how the Product Development Partnership (PDP) model draws together the private sector, funders, academia and many other stakeholders to deliver innovations that will save thousands of lives.
Whilst this exciting news represents a major step forward in the fight against malaria, it should be noted that the implementation of RTS,S is a complement to the deployment of effective prevention tools, such as Insecticide Treated Nets (ITNs) or Indoor Residual Sprays (IRS), and not a replacement.
As such it should not come at the detriment of efforts to support the continued innovation, development and deployment of effective prevention tools such as Insecticide Treated Nets (ITNs), Indoor Residual Sprays (IRS) and potential new product classes such as Attractive Targeted Sugar Baits (ATSB®). To defeat malaria a toolbox of interventions across drugs, vaccines and vector control will still be needed, but now we will celebrate this ground-breaking news which takes us all one step closer to eradicating malaria for good.
Tech Update Summer 2021 2nd September 2021
Download the Tech Updates highlighting vector biology and control news, publications and resources.
Given the breadth of vector control-related literature, we are unable to include all relevant work. These updates are intended to focus primarily on Anopheles biology and a subset of control topics with global relevance.
Any views expressed in the updates do not necessarily reflect the views or opinions of IVCC. In many cases, we directly quote sections of published work. Mention of trade names or commercial products is solely for the purpose of providing specific information and does not imply recommendation or endorsement by IVCC or its funders.
World Mosquito Day 2021 – 20th August 2021 18th August 2021
Today is World Mosquito Day. On this day in 1897, Sir Ronald Ross discovered that Anopheles mosquitoes were responsible for the transmission of the malaria parasite. Ross’s discovery revolutionized our understanding of how to prevent malaria. Steps could be taken to target the mosquito vector to control the disease. One hundred and twenty-four years later, mosquito vector control remains a mainstay of malaria prevention. It has been estimated that between 2000 and 2015, 450 million clinical cases of malaria were averted by the widespread distribution of insecticide-treated bed nets.
Until 2019, all insecticide-treated bed nets distributed throughout Africa were treated with only one class of insecticide, pyrethroids, contributing to increasing levels of pyrethroid resistance in mosquito populations. Increases in pyrethroid resistance threaten the gains that have been made against malaria since higher levels of resistance may reduce the ability of pyrethroid-based bed nets to protect people from infectious mosquito bites.
The IVCC led New Nets Project (NNP), established in 2018 with co-funding from Unitaid and the Global Fund and complementary funding provided by the Bill & Melinda Gates Foundation and USAID, works with the next generation of nets, which are dual-insecticide nets, containing both a pyrethroid and a second insecticide. BASF’s Interceptor® G2 nets contain a pyrethroid and chlorfenapyr, and DCT’s Royal Guard® nets contain a pyrethroid plus pyriproxyfen. NNP was established with the goal of making the latest resistance-breaking net technology more widely available and affordable to malaria programmes throughout Africa by managing the pilot deployment of nets with reduced pricing via a co-payment mechanism and volume guarantee provided to BASF by MedAccess, while also establishing the evidence needed to support a policy decision by the World Health Organization (WHO) to recommend dual-insecticide nets over standard pyrethroid nets.
Although there is entomological data available showing increased mosquito mortality in hut studies for the Interceptor® G2 net and reduced mosquito fecundity for the Royal Guard® net compared to a standard pyrethroid net, two randomized control trials providing epidemiological data are required by the WHO prior to issuing a recommendation. We eagerly anticipate results from one such study in Tanzania (funded by Wellcome Trust) that will be available later this year, as well as results from a study in Benin as part of the New Nets Project that will be available in 2022. Both studies are being led by the London School of Hygiene and Tropical Medicine.
Over 20 million Interceptor® G2 and 1.5 million Royal Guard® nets have been distributed through NNP in 8 countries since 2019. By the end of the project in 2022, over 35 million Interceptor® G2 nets will have been distributed, data from the two randomized control trials will be available, and five observational studies will have collected entomological, anthropological, incidence, prevalence, net durability, and cost-effectiveness data to support impact modelling and country deployment decisions.
NNP will not only result in accelerated access to new nets but will also establish critical guidance to countries looking for the best value for money in controlling malaria. NNP is currently over one year ahead of schedule in reaching the Interceptor® G2 volume guarantee and associated price reductions. This has helped to lay the foundation for the Global Fund’s Net Transition Initiative that will help partner countries access additional new nets for the same price as standard pyrethroid nets and conduct additional research pending WHO’s review of the data and subsequent decision on their policy recommendation.
The development and deployment of dual-insecticide nets throughout Africa continue our fight against the mosquito vector of malaria first recognized by Sir Ronald Ross. Today, on World Mosquito Day, let us reflect on his seminal discovery and all the advances we have made since in combatting malaria, while also recommitting ourselves to eliminating this mosquito-borne disease.